Recurrent Skin Langerhan Cell Histiocytosis Successfully Treated With Indomethacin Monotherapy
Document Type
Article
Publication Date
4-3-2020
Publication Title
Journal of pediatric hematology/oncology
Abstract
Langerhans cell histiocytosis (LCH) often has a recurrent and refractory course despite multiagent treatment modalities. Common relapse treatments include intense or prolonged cytotoxic chemotherapy regimens. There are a few prior reports that the nonsteroidal anti-inflammatory drug indomethacin demonstrated activity against bone LCH. Here we report indomethacin as a successful treatment for a case of chronic skin LCH that failed multiple prior chemotherapy regimens. This experience supports the need for trials to investigate indomethacin as a treatment for LCH both in the relapsed or refractory setting as well as potential combination or maintenance therapy in newly diagnosed patients.
PubMed ID
30951019
Volume
42(8)
Recommended Citation
Dhir, Aditi; Kelly, David R.; Watts, Raymond G.; and Kutny, Matthew A., "Recurrent Skin Langerhan Cell Histiocytosis Successfully Treated With Indomethacin Monotherapy" (2020). School of Medicine Faculty Publications. 1747.
https://digitalscholar.lsuhsc.edu/som_facpubs/1747